Brief: Pherecydes Pharma Get ANSM Approval For PhagoDAIR Programme

Pherecydes Pharma SA

22/12/2021 06:06

Dec 22 (Reuters) - PHERECYDES PHARMA SA  ALPHE.PA :
    * PHERECYDES PHARMA OBTAINS ANSM APPROVAL FOR ITS PHAGODAIR
PROGRAM, THE WORLD'S FIRST STUDY IN PRECISION PHAGE THERAPY
    * PHAGODAIR IS A PHASE I/II CLINICAL STUDY WITH
ANTI-STAPHYLOCOCCUS AUREUS PHAGES IN TREATMENT OF OSTEOARTICULAR
INFECTIONS OF PROSTHESES CAUSED BY THIS BACTERIUM
    * PATIENT ENROLLMENT SHOULD BEGIN DURING SPRING OF 2022,
SUBJECT
TO CPP (PATIENT PROTECTION COMMITTEE) APPROVAL
    * FIRST RESULTS OF STUDY ARE EXPECTED IN SUMMER OF 2023
    * ASSESSMENT WILL BE UNDERTAKEN 12 WEEKS AFTER DAIR SURGICAL
PROCEDURE, AND PATIENTS WILL CONTINUE TO BE MONITORED FOR 2
YEARS
    * RESULTS ARE EXPECTED IN SUMMER OF 2023 AND MONITORING WILL
CONTINUE THROUGH TO FIRST HALF OF 2025
    * DEPENDING ON PRELIMINARY RESULTS OF PHASE I/II STUDY,
PHERECYDES
PHARMA INTENDS TO CARRY OUT A PHASE III STUDY IN SAME INDICATION
THAT COULD BEGIN AT END OF 2023

Source text for Eikon:  ID:nBw1x3P4ba 
Further company coverage:  ALPHE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))